Rebetron (Schering-Plough) en es it fr

Rebetron (Schering-Plough) Brand names, Rebetron (Schering-Plough) Analogs

Rebetron (Schering-Plough) Brand Names Mixture

  • No information avaliable

Rebetron (Schering-Plough) Chemical_Formula

C860H1353N229O255S9

Rebetron (Schering-Plough) RX_link

http://www.rxlist.com/cgi/generic2/ribav.htm

Rebetron (Schering-Plough) fda sheet

Rebetron (Schering-Plough) msds (material safety sheet)

Rebetron (Schering-Plough) Synthesis Reference

No information avaliable

Rebetron (Schering-Plough) Molecular Weight

19269.1

Rebetron (Schering-Plough) Melting Point

No information avaliable

Rebetron (Schering-Plough) H2O Solubility

No information avaliable

Rebetron (Schering-Plough) State

No information avaliable

Rebetron (Schering-Plough) LogP

-0.339

Rebetron (Schering-Plough) Dosage Forms

Capsule; Powder for solution; Solution (injection)

Rebetron (Schering-Plough) Indication

For treatment of Hepatitis C

Rebetron (Schering-Plough) Pharmacology

Upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase) and protein kinase R.

Rebetron (Schering-Plough) Absorption

No information avaliable

Rebetron (Schering-Plough) side effects and Toxicity

No information avaliable

Rebetron (Schering-Plough) Patient Information

BIOD00015.html

Rebetron (Schering-Plough) Organisms Affected

Humans and other mammals